First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Ligand Pharmaceuticals Incorporated (LGND): the developments shaping its investment case

    Follow the evidence affecting Ligand Pharmaceuticals Incorporated's valuation assumptions, demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Ligand Pharmaceuticals Incorporated · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-24 · 2 reports
    Ligand Pharmaceuticals Incorporated to Acquire AvenCell Therapeutics, Inc. ($47M)
    Channel: Ligand is providing financing in exchange for royalties on AvenCell's pipeline assets. This deal structure allows Ligand to gain exposure to potential future drug revenues without the full R&D and operational costs of developing the assets itself. The impact is contingent on AvenCell's clinical succ
    Bullish· 1-5y
    2026-09-24
    Ligand Pharmaceuticals Incorporated Follow-On — $6M
    Channel: Capital allocation, investment in early-stage biotech, potential future royalty streams, and immediate cash outflow.
    mixed· 1-3m
    2026-08-27
    MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial
    Channel: Potential future competition in the hypoparathyroidism market.
    watch· 1-5y

    Evidence affecting valuation assumptions

    Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

    DateAssumptionDirectionInterpretation
    2026-09-24multipleBearishIncremental float typically compresses near-term multiple absent revenue acceleration.
    2026-09-24share_countBullishPrimary equity issuance increases diluted share count.
    2026-06-23share_countBullishIssuance of convertible senior notes creates potential future dilution of share count upon conversion.
    2026-06-22share_countBearishRepurchase reduces shares outstanding.
    2026-06-22interest_expenseBullishCoupon adds to interest expense until conversion.
    2026-06-22dilutionBullishConvertible issuance creates contingent dilution at conversion price.
    2026-06-12share_countBullishStock component of consideration dilutes existing acquirer holders.
    2026-06-12net_debtBullishCash component of consideration is typically debt-funded, raising net debt.
    2026-06-12revenueBullishAcquisition adds target revenue to acquirer P&L on close.

    Event impact log

    4 events mapped to LGND since 2026-08-27. Evidence through 2026-09-24.

    DateEventChannelDirectionHorizonImpact
    2026-09-24Ligand Pharmaceuticals Incorporated Follow-On — $6MCapital allocation, investment in early-stage biotech, potential future royalty streams, and immediate cash outflow.mixed1-3m0.40
    2026-09-24Ligand Pharmaceuticals Incorporated to Acquire AvenCell Therapeutics, Inc. ($47M)Ligand is providing financing in exchange for royalties on AvenCell's pipeline assets. This deal structure allows Ligand to gain exposure to potential future drug revenues without the full R&D and operational costs of developing the assets itself. The impact is contingent on AvenCell's clinical succBullish1-5y0.60
    2026-09-22Ligand Pharmaceuticals Incorporated to Acquire Sydnexis, Inc. ($23M)Direct acquisition of a revenue-generating asset (royalty stream).Bullish1-5y0.60
    2026-08-27MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize TrialPotential future competition in the hypoparathyroidism market.watch1-5y0.10

    Continue this research

    Build your Ligand Pharmaceuticals Incorporated investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the LGND entity page →

    Research Ligand Pharmaceuticals Incorporated · $399/mo